marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-31-2024
Bio-Rad Laboratories Balance Sheet 2011-2024 | BIO
Annual Balance Sheet Bio-Rad Laboratories
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
836 M | 800 M | -424 M | -624 M | -221 M | 7.9 M | 51.2 M | -21.7 M | -21.5 M | 22.7 M | 106 M | 271 M | 158 M |
Long Term Debt |
1.2 B | 1.2 B | 10.5 M | 1.8 M | 13.6 M | 439 M | 435 M | 434 M | 436 M | 436 M | 436 M | 732 M | 732 M |
Long Term Debt Current |
40.4 M | 36.3 M | 36.4 M | 36.5 M | 35.4 M | - | - | - | - | - | 200 K | 200 K | 600 K |
Total Non Current Liabilities |
- | - | - | - | 1.35 B | 1.14 B | 840 M | 792 M | 780 M | 709 M | 715 M | 956 M | 893 M |
Total Current Liabilities |
523 M | 569 M | 681 M | 632 M | 905 M | 451 M | 503 M | 471 M | 441 M | 447 M | 487 M | 470 M | 459 M |
Total Liabilities |
3.56 B | 3.89 B | 4.11 B | 3.09 B | 2.25 B | 1.59 B | 1.34 B | 1.26 B | 1.22 B | 1.16 B | 1.2 B | 1.43 B | 1.35 B |
Deferred Revenue |
51.1 M | 52.2 M | 50.9 M | 42.5 M | 33.7 M | 26.9 M | 28.2 M | 31 M | 29.7 M | 26.7 M | 26.4 M | 26.3 M | 24.3 M |
Retained Earnings |
9.26 B | 9.9 B | 13.5 B | 9.27 B | 5.47 B | 3.72 B | 1.83 B | 1.84 B | 1.81 B | 1.69 B | 1.61 B | 1.52 B | 1.36 B |
Total Assets |
12.3 B | 13.5 B | 17.8 B | 13 B | 8.01 B | 5.61 B | 4.27 B | 3.85 B | 3.71 B | 3.34 B | 3.39 B | 3.44 B | 3.1 B |
Cash and Cash Equivalents |
404 M | 434 M | 471 M | 662 M | 661 M | 432 M | 384 M | 456 M | 458 M | 413 M | 332 M | 463 M | 574 M |
Book Value |
8.74 B | 9.62 B | 13.7 B | 9.88 B | 5.76 B | 4.02 B | 2.93 B | 2.59 B | 2.49 B | 2.19 B | 2.19 B | 2.01 B | 1.74 B |
Total Shareholders Equity |
8.74 B | 9.62 B | 13.7 B | 9.89 B | 5.76 B | 4.02 B | 2.93 B | 2.58 B | 2.49 B | 2.19 B | 2.19 B | 2.01 B | 1.74 B |
All numbers in USD currency
Quarterly Balance Sheet Bio-Rad Laboratories
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | - | 1.2 B | 10.5 M | 10.6 M | 10.8 M | 10.9 M | 12.3 M | 12.2 M | 12.3 M | 12.3 M | 13.6 M | 438 M | 13.6 M | 13.6 M | 439 M | 439 M | 439 M | 439 M | 435 M | 435 M | 435 M | 435 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 434 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 733 M | 436 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M | 732 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.12 B | 2.91 B | 3.56 B | 3.48 B | 3.53 B | 3.9 B | 3.89 B | 3.6 B | - | 4.19 B | 4.11 B | 4.62 B | 3.52 B | 3.32 B | 3.09 B | 3.09 B | 3.09 B | 3.09 B | 2.25 B | 2.25 B | 2.25 B | 2.25 B | 1.59 B | 1.59 B | 1.59 B | 1.59 B | 1.34 B | 1.34 B | 1.34 B | 1.34 B | 1.27 B | 1.26 B | 1.26 B | 1.26 B | 1.22 B | 1.22 B | 1.22 B | 1.22 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.43 B | 1.43 B | 1.43 B | 1.43 B | 1.35 B | 1.35 B | 1.35 B | 1.35 B |
Deferred Revenue |
48.9 M | 52 M | 55.1 M | 49.1 M | 53.7 M | 56.9 M | 52.2 M | 58 M | - | 59.3 M | 50.9 M | 47.9 M | 47.5 M | 48 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 33.7 M | 33.7 M | 33.7 M | - | 26.9 M | - | - | - | 28.2 M | - | - | - | 31 M | - | - | - | 29.7 M | - | - | - | 26.7 M | - | - | - | 26.4 M | - | - | - | 26.3 M | - | - | - | 24.3 M | - | - | - |
Retained Earnings |
8.13 B | 7.48 B | 9.64 B | 8.91 B | 8.8 B | 9.97 B | 9.9 B | 9.05 B | - | 10.1 B | 13.5 B | 15.1 B | 11.2 B | 10.2 B | 9.27 B | 9.27 B | 9.27 B | 9.27 B | 5.47 B | 5.47 B | 5.47 B | 5.47 B | 3.72 B | 3.72 B | 3.72 B | 3.72 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.84 B | 1.84 B | 1.84 B | 1.81 B | 1.81 B | 1.81 B | 1.81 B | 1.69 B | 1.69 B | 1.69 B | 1.69 B | 1.61 B | 1.61 B | 1.61 B | 1.61 B | 1.53 B | 1.53 B | 1.52 B | 1.52 B | 1.36 B | 1.36 B | 1.36 B | 1.36 B |
Total Assets |
10.6 B | 9.69 B | 12.6 B | 11.9 B | 12 B | 13.7 B | 13.5 B | 12.1 B | - | 14.4 B | 17.8 B | 20 B | 15.1 B | 13.9 B | 13 B | 13 B | 13 B | 13 B | 8.01 B | 8.01 B | 8.01 B | 8.01 B | 5.61 B | 5.61 B | 5.61 B | 5.61 B | 4.27 B | 4.27 B | 4.27 B | 4.27 B | 3.85 B | 3.85 B | 3.85 B | 3.85 B | 3.71 B | 3.71 B | 3.71 B | 3.71 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.39 B | 3.39 B | 3.39 B | 3.39 B | 3.44 B | 3.44 B | 3.44 B | 3.44 B | 3.1 B | 3.1 B | 3.1 B | 3.1 B |
Cash and Cash Equivalents |
410 M | 407 M | 433 M | 458 M | 390 M | 464 M | 434 M | 518 M | 597 M | 802 M | 471 M | 860 M | 733 M | 673 M | 662 M | 662 M | 662 M | 662 M | 661 M | 661 M | 661 M | 661 M | 432 M | 432 M | 432 M | 432 M | 384 M | 384 M | 384 M | 384 M | 456 M | 456 M | 456 M | 456 M | 458 M | 458 M | 458 M | 458 M | 413 M | 413 M | 413 M | 413 M | 332 M | 332 M | 332 M | 332 M | 463 M | 463 M | 463 M | 463 M | 574 M | 574 M | 574 M | 574 M |
Book Value |
7.49 B | 6.78 B | 9.05 B | 8.42 B | 8.45 B | 9.76 B | 9.62 B | 8.45 B | - | 10.2 B | 13.7 B | 15.3 B | 11.6 B | 10.6 B | 9.88 B | 9.88 B | 9.88 B | 9.88 B | 5.76 B | 5.76 B | 5.76 B | 5.76 B | 4.02 B | 4.02 B | 4.02 B | 4.02 B | 2.93 B | 2.93 B | 2.93 B | 2.93 B | 2.58 B | 2.59 B | 2.59 B | 2.59 B | 2.49 B | 2.49 B | 2.49 B | 2.49 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.02 B | 2.02 B | 2.01 B | 2.01 B | 1.74 B | 1.74 B | 1.74 B | 1.74 B |
Total Shareholders Equity |
7.49 B | 6.78 B | 9.05 B | 8.42 B | 8.45 B | 9.76 B | 9.62 B | 8.48 B | 8.95 B | 10.2 B | 13.7 B | 15.3 B | 11.6 B | 10.6 B | 9.88 B | 9.88 B | 9.88 B | 9.88 B | 5.76 B | 5.76 B | 5.76 B | 5.76 B | 4.02 B | 4.02 B | 4.02 B | 4.02 B | 2.93 B | 2.93 B | 2.93 B | 2.93 B | 2.58 B | 2.59 B | 2.59 B | 2.59 B | 2.49 B | 2.49 B | 2.49 B | 2.49 B | 2.18 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.19 B | 2.02 B | 2.02 B | 2.01 B | 2.01 B | 1.74 B | 1.74 B | 1.74 B | 1.74 B |
All numbers in USD currency